Aim: Activation of protein kinase C (PKC) has been implicated in the pathogenesis of diabetic nephropathy where therapy targeting the β isoform of this enzyme has been examined. However, PKC-β is also increased in various forms of human glomerulonephritis, including IgA nephropathy. Accordingly, we sought to examine the effects of PKC-β inhibition in the Thy1.1 model of mesangial proliferative glomerulonephritis. Methods: Following administration of monoclonal OX-7, anti-rat Thy-1.1 antibody, Male Wistar rats were randomized to receive either the PKC-β inhibitor, ruboxistaurin (10 mg/kg per day in chow) or vehicle. Animals were then examined 6 days later. Results: PKC-β inhibition was associated with reductions in mesangial cellularity and extracellular matrix deposition. Proteinuria was, however, unaffected. In vitro, PKC-β inhibition showed modest, dose-dependent reductions in mesangial cell 3H-thymidine and 3H-proline incorporations, indices of cell proliferation and collagen synthesis, respectively. Conclusion: The amelioration of the pathological findings of experimental mesangial proliferative glomerulonephritis by PKC-β inhibition suggests the potential clinical utility of this approach as a therapeutic strategy in non-diabetic glomerular disease. This paper describes the amelioration of the pathological findings by PKC-β inhibitor, ruboxistaurin, in Thy1.1 model of mesangial proliferative glomerulonephritis. These data, together with the demonstrated safety of ruboxistaurin in phase II-III clinical trials in diabetes, suggest that PKC-β inhibition might also be a suitable therapeutic strategy in IgA nephropathy.
- IgA nephropathy
- mesangial proliferative glomerulonephritis
- platelet-derived growth factor
- protein kinase C
ASJC Scopus subject areas